Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.47 |
| ▸ | KLK7 | P49862 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848153 | 0.86 | TPSAB1 (0.47) | SIRT2SIRT1SIRT3SYKCPB1 | |
| SCHEMBL21460905 | 0.84 | MAPT (0.51) | KLK7KLK5SYKMAPTTPSAB1 | |
| SCHEMBL21460902 | 0.84 | MAPT (0.51) | KLK7KLK5SYKMAPTTPSAB1 | |
| SCHEMBL4857149 | 0.84 | MAPT (0.58) | SIRT2KLK7KLK5CTSSCTSL | |
| SCHEMBL4848148 | 0.83 | CPB1 (0.49) | SIRT2KLK7KLK5CTSSCTSL | |
| SCHEMBL8068255 | 0.81 | TPSAB1 (0.46) | KLK7KLK5SYKMAPTTPSAB1 | |
| SCHEMBL12148814 | 0.81 | MAPT (0.62) | SIRT2KLK7KLK5SIRT1SIRT3 | |
| SCHEMBL30902797 | 0.81 | MAPT (0.62) | SIRT2KLK7KLK5CTSSCTSL | |
| SCHEMBL10242708 | 0.81 | KLK7 (0.54) | SIRT2KLK7KLK5CTSSSIRT1 | |
| SCHEMBL5309220 | 0.81 | CTSL (0.62) | SIRT2KLK7KLK5CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | AICURIS GMBH & CO. KG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | SIRT2 115/4885KLK7 3789/4885KLK5 2790/4885 |
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | ARG1, HRH3, H1-0 | SIRT2 264/4885KLK7 4300/4885KLK5 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.